Teachers Retirement System of The State of Kentucky Has $9.16 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Teachers Retirement System of The State of Kentucky increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 43.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 138,755 shares of the medical research company's stock after acquiring an additional 42,059 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Edwards Lifesciences were worth $9,156,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Stableford Capital II LLC lifted its position in shares of Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company's stock worth $533,000 after purchasing an additional 159 shares in the last quarter. Purus Wealth Management LLC lifted its holdings in Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company's stock worth $297,000 after buying an additional 160 shares in the last quarter. Busey Bank boosted its position in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company's stock valued at $816,000 after buying an additional 165 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Edwards Lifesciences by 7.4% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company's stock worth $224,000 after acquiring an additional 166 shares during the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after acquiring an additional 166 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Oppenheimer reiterated an "outperform" rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Wells Fargo & Company dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Barclays raised their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an "overweight" rating in a research note on Monday, December 2nd. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group raised their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, December 5th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus price target of $78.65.

Edwards Lifesciences Stock Down 0.9 %

Shares of Edwards Lifesciences stock traded down $0.65 during trading on Friday, reaching $73.32. The stock had a trading volume of 3,092,539 shares, compared to its average volume of 4,642,550. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $43.24 billion, a price-to-earnings ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a fifty day moving average price of $69.26 and a two-hundred day moving average price of $74.19.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm posted $0.59 EPS. The business's revenue was up 8.9% on a year-over-year basis. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company's stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock valued at $2,323,150 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.